This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Strong Buy Alerts: AppLovin & 2 More Momentum Stocks for Big Gains
by Tirthankar Chakraborty
AppLovin, Build-A-Bear Workshop, and Tenet Healthcare emerge as top Driehaus momentum picks, backed by strong earnings and trend signals.
THCPositive Net Change BBWNegative Net Change APPPositive Net Change
medical retail tech-stocks
FONAR Stock Dips Post FY25 Earnings on Lower Profit and Higher Costs
by Zacks Equity Research
FONR reports higher costs and lower profits in fiscal 2025, despite increases in scan volumes and imaging service revenues.
FONRNegative Net Change
earnings medical medical-devices
CVS vs. EVH: Which Value-Based Care Stock Deserves Investor Attention?
by Moumi Mondal
CVS shows revenue growth and raised guidance, while EVH faces revenue declines but pursues oncology deals and efficiency gains.
CVSPositive Net Change EVHNegative Net Change
medical medical-devices
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
by Zacks Equity Research
BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.
WSTNegative Net Change MEDPPositive Net Change BWAYNegative Net Change NVSTNegative Net Change
medical medical-devices
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY Announces New Late-Stage Data on Skin Disease Drug
by Zacks Equity Research
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
NVSNegative Net Change INCYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
LH Stock Rises on Acquisition of BioReference Health's Select Assets
by Zacks Equity Research
Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.
LHPositive Net Change MASINegative Net Change OPKNo Net Change PAHCNegative Net Change NVSTNegative Net Change
medical
Green Thumb Launches $50M Buyback: Time to Get Bullish on the Stock?
by Sundeep Ganoria
GTBIF launches a $50 million share buyback program, signaling confidence in long-term growth despite market and pricing pressures.
TLRYNegative Net Change GTBIFNegative Net Change CURLFNegative Net Change
marijuana medical
CAH Strengthens Distribution With New Consumer Health Logistics Hub
by Zacks Equity Research
Cardinal Health opens a 350,000-square-foot Consumer Health Logistics Center in Ohio, strengthening its pharmaceutical supply chain and advancing its multiyear infrastructure expansion strategy.
BSXNegative Net Change CAHPositive Net Change WSTNegative Net Change MEDPPositive Net Change
medical medical-devices
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
by Zacks Equity Research
GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.
BSXNegative Net Change WSTNegative Net Change MEDPPositive Net Change GEHCNegative Net Change
medical medical-devices
Top Research Reports for Alphabet, IBM & Merck
by Mark Vickery
Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.
IBMPositive Net Change MRKPositive Net Change MUPositive Net Change MFCNegative Net Change SDPositive Net Change GOOGLNegative Net Change CFGPositive Net Change NRXSPositive Net Change
computers internet medical oil-energy pharmaceuticals
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
by Sundeep Ganoria
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
HCA Healthcare Trades at a Premium: Buy, Hold, or Avoid the Stock?
by Kaibalya Pravo Dey
HCA trades above peers on valuation, backed by strong cash flow and buybacks, but weighed by debt and sector headwinds.
UHSPositive Net Change THCPositive Net Change HCANegative Net Change
medical
Danaher's Life Sciences Segment Shrinks: What's the Path Forward?
by Zacks Equity Research
DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.
LHPositive Net Change DHRPositive Net Change CVSPositive Net Change
medical
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
by Zacks Equity Research
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
TMONegative Net Change CAHPositive Net Change MASINegative Net Change PAHCNegative Net Change
medical medical-devices
Should You Continue to Hold Integra Stock in Your Portfolio Now?
by Zacks Equity Research
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.
CAHPositive Net Change IARTNegative Net Change MASINegative Net Change PAHCNegative Net Change
medical medical-devices
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
by Zacks Equity Research
Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
ISRGNegative Net Change WSTNegative Net Change MEDPPositive Net Change NVSTNegative Net Change
medical medical-devices
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
by Debanjana Dey
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
TDOCPositive Net Change GDRXNegative Net Change HIMSNegative Net Change
medical medical-devices
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
by Zacks Equity Research
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
NVSNegative Net Change RHHBYPositive Net Change GLUENegative Net Change
biotechs medical pharmaceuticals
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
by Zacks Equity Research
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
WSTNegative Net Change MEDPPositive Net Change NVSTNegative Net Change GEHCNegative Net Change
medical medical-devices
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
by Zacks Equity Research
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BDXPositive Net Change HSICNegative Net Change STEPositive Net Change SOLVNegative Net Change
medical medical-devices
Company News for Sep 16, 2025
by Zacks Equity Research
Companies in The News Are: NVDA,HIMS,MSFT,NFLX
MSFTPositive Net Change NFLXPositive Net Change NVDANegative Net Change HIMSNegative Net Change
medical semiconductor tech-stocks
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
by Ahan Chakraborty
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
by Zacks Equity Research
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
MASINegative Net Change MYGNNegative Net Change PAHCNegative Net Change GEHCNegative Net Change
medical
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
by Sridatri Sarkar
Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.
NNOXNegative Net Change GEHCNegative Net Change TEMNegative Net Change
medical